Camurus
| File:Camurus Logo.svg | |
| Company type | Public (Aktiebolag) |
|---|---|
| Nasdaq Stockholm: CAMX | |
| Industry | Pharmaceutical |
| Revenue | Increase 1.75 billion kr (2023)[1] |
Number of employees | 213[1] |
Camurus AB is a Swedish research-based pharmaceutical company specializing in the development and commercialization of medicines for the treatment of serious and chronic diseases. Founded in 1991 by scientists with expertise in lipid phase structures, the company is headquartered in Lund, Sweden. The company is listed on Nasdaq Stockholm, Large Cap under the ticker CAMX.
Company profile
Camurus clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. New products are conceived based on R&D expertise and applying the company´s proprietary injection depot technology, FluidCrystal, to active substances with available positive clinical data on efficacy and safety.
Technologies
Camurus specializes in the development of lyotropic liquid crystal structures for pharmaceutical drug delivery. These structures consist of well-defined three-dimensional formations with both lipophilic and hydrophilic domains, whose configuration depends on environmental conditions.[2] This unique technology enables the encapsulation and transport of Active pharmaceutical ingredients (APIs), including small molecules, peptides, and proteins, throughout the body. The structures also support controlled drug release and protect fragile, short half-life molecules, such as amino-acid-based drugs, from degradation.
FluidCrystal® technology
Camurus' FluidCrystal technology is a long-acting injectable depot system designed for sustained drug delivery. By encapsulating the drug compound within nanoscale structures, the technology enables the controlled release of therapeutic levels of active substances over extended periods from a single injection. This makes it particularly suitable for the delivery of peptides, proteins, and small molecule drugs in treatments requiring long-term efficacy and reduced dosing frequency.[3]
Products
CAM2029
CAM2029 is an investigational medicinal product currently being evaluated for the treatment of acromegaly, neuroendocrine tumors and polycystic liver disease.
CAM2038
CAM2038 is a long-acting injectable treatment for opioid dependence (opioid use disorder), based on the well-established opioid treatment buprenorphine. The sustained-release injection depot provides weekly and monthly dosing options, offering patients greater convenience compared to daily treatments. CAM2038 has been approved by regulatory authorities and is commercially available in the EU, United Kingdom, Australia, and the United States under two different trade names.
References
- ↑ 1.0 1.1 "Camurus Annual Report 2023" (PDF). Camurus. Camurus AB. 2023. Retrieved 2024-12-03.
- ↑ Prinsen, Peter; Odijk, Theo (2006). "Fluid-crystal coexistence for proteins and inorganic nanocolloids: Dependence on ionic strength". Journal of Chemical Physics. 125 (7): 4903. arXiv:cond-mat/0604275. Bibcode:2006JChPh.125g4903P. doi:10.1063/1.2336423. PMID 16942376. S2CID 18700145.
- ↑ "Brochure" (PDF). ondrugdelivery.com. Archived from the original (PDF) on 2016-01-09. Retrieved 2014-09-18.